Comparable stake leader
Commodore Capital LP
SEC ownership of Editas Medicine, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001650664.
Disclosed value leader
Commodore Capital LP
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- EDIT on Nasdaq
- Parsed ownership sources
-
13D/G and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Commodore Capital LP
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Commodore Capital LP
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001650664
- Issuer location
- Cambridge, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Editas Medicine, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Commodore Capital LP
Disclosed value leader
Commodore Capital LP
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
13F
Lead comparable stake: 9.9%
13D/G row: Commodore Capital LP
Showing 1-8 of 50 holder rows.
Quick read
Commodore Capital LP leads the comparable SEC ownership view at 9.9%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Commodore Capital LP's linked filing trail.
Comparable ownership
Top 5
Commodore Capital LP
9.9%
TCG Crossover GP III, LLC
9.9%
ADAR1 Capital Management, LLC
5.8%
RA CAPITAL MANAGEMENT, L.P.
5.8%
BlackRock, Inc.
5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Commodore Capital LP |
13D/G
13F
Company
|
9.9%
|
$51,025,650
16,045,802 shares
|
$0 | 26 May 2026 |
| TCG Crossover GP III, LLC |
13D/G
|
9.9%
|
$50,240,817
15,798,999 shares
|
$0 | 27 May 2026 |
| ADAR1 Capital Management, LLC |
13F
13D/G
Company
|
5.8%
from 13D/G
|
$28,800,360
8,889,000 shares
|
— | 30 Jun 2026 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
Company
|
5.8%
from 13D/G
|
$28,800,360
8,889,000 shares
|
— | 30 Jun 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5%
from 13D/G
|
$34,311,568
10,589,990 shares
|
— | 30 Jun 2026 |
| TCG Crossover Management, LLC |
13F
Company
|
7.2%
|
$36,000,000
11,111,111 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
4%
|
$19,897,929
6,141,336 shares
|
— | 30 Jun 2026 |
| Paradigm Biocapital Advisors LP |
13F
Company
|
3.6%
|
$18,100,665
5,586,625 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$105,183.
Buys
$0
Insiders: 0
Sells
$105,183
Insiders: 3
Net
-$105,183
Shares: -42,335
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 42,335
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 22,181 | $0 | $59,678 | -$59,678 |
| 3-6 | 0 | 6,617 | $0 | $13,364 | -$13,364 |
| 6-9 | 0 | 6,777 | $0 | $14,592 | -$14,592 |
| 9-12 | 0 | 6,760 | $0 | $17,550 | -$17,550 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-19 of 19 reporting-owner rows connected to Editas Medicine, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
19
Largest Forms 3/4/5 holder
Michelle Robertson
Net 12M change
-$105,183
Latest report
06 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Michelle Robertson | Evp, Chief Financial Officer | $1,161,750 | Mixed | 11 May 2023 | ||
| Bruce Eaton | Evp, Cbo And Cto | $815,012 | Filing P/S | 05 Dec 2023 | ||
| Mark S. Shearman | Evp, Chief Scientific Officer | $714,410 | Mixed | 13 Feb 2023 | ||
| Gilmore Neil O'Neill | CEO, Director | $670,718 | -$79,018 | -11% | Filing P/S | 03 Jun 2026 |
| Baisong Mei | Evp, Chief Medical Officer | $277,003 | Filing P/S | 03 Dec 2024 | ||
| Lisa Anne Michaels | EVP/Chief Medical Officer | $247,094 | Mixed | 22 Dec 2021 | ||
| Erick Lucera | Evp, Chief Financial Officer | $192,841 | Filing P/S | 08 Mar 2025 | ||
| Linda C. Burkly | Evp, Chief Scientific Officer | $166,525 | -$20,023 | -11% | Filing P/S | 28 Jul 2026 |
| Amy Parison | SVP, Chief Financial Officer | $36,873 | -$6,142 | -14% | Filing P/S | 03 Aug 2026 |
| Jessica Hopfield | Director | Mixed | 17 Jun 2026 | |||
| Patrick Thomas Ellinor II | Director | Mixed | 06 Aug 2026 | |||
| Emma Reeve | Director | Mixed | 30 May 2024 | |||
| Akshay Vaishnaw | Director | Mixed | 30 May 2024 | |||
| David Scadden | Director | Mixed | 17 Jun 2026 | |||
| Meeta Chatterjee | Director | Mixed | 30 May 2024 | |||
| Elliott M. Levy | Director | Mixed | 17 Jun 2026 | |||
| James C. Mullen | CEO, Director | Mixed | 14 Apr 2022 | |||
| Bernadette Connaughton | Director | Mixed | 17 Jun 2026 | |||
| Andrew Hirsch | Director | Mixed | 17 Jun 2026 |
Recent insider transactions for Editas Medicine, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Patrick Thomas Ellinor II | EDIT | Stock Option (right to buy) | Award | 103,400 | 103,400 | 06 Aug 2026 | Direct | |||
| Amy Parison | EDIT | Common Stock | Sale | -4.53% | $1,749 | $2.58 | -678 | 14,292 | 03 Aug 2026 | Direct |
| Linda C. Burkly | EDIT | Common Stock | Sale | -7.32% | $13,158 | $2.67 | -4,928 | 62,369 | 28 Jul 2026 | Direct |
| Bernadette Connaughton | EDIT | Stock Option (right to buy) | Award | 51,700 | 51,700 | 17 Jun 2026 | Direct | |||
| Jessica Hopfield | EDIT | Stock Option (right to buy) | Award | 51,700 | 51,700 | 17 Jun 2026 | Direct | |||
| Andrew Hirsch | EDIT | Stock Option (right to buy) | Award | 51,700 | 51,700 | 17 Jun 2026 | Direct | |||
| David Scadden | EDIT | Stock Option (right to buy) | Award | 51,700 | 51,700 | 17 Jun 2026 | Direct | |||
| Elliott M. Levy | EDIT | Stock Option (right to buy) | Award | 51,700 | 51,700 | 17 Jun 2026 | Direct | |||
| Amy Parison | EDIT | Common Stock | Sale | -3.01% | $1,253 | $2.70 | -464 | 14,970 | 03 Jun 2026 | Direct |
| Gilmore Neil O'Neill | EDIT | Common Stock | Sale | -5.83% | $41,543 | $2.70 | -15,380 | 248,313 | 03 Jun 2026 | Direct |
| Linda C. Burkly | EDIT | Common Stock | Sale | -1.07% | $1,974 | $2.70 | -731 | 67,297 | 03 Jun 2026 | Direct |
| Gilmore Neil O'Neill | EDIT | Stock Option (right to buy) | Award | 1,015,200 | 1,015,200 | 12 Mar 2026 | Direct | |||
| Amy Parison | EDIT | Stock Option (right to buy) | Award | 292,856 | 292,856 | 12 Mar 2026 | Direct | |||
| Linda C. Burkly | EDIT | Stock Option (right to buy) | Award | 292,856 | 292,856 | 12 Mar 2026 | Direct | |||
| Gilmore Neil O'Neill | EDIT | Common Stock | Sale | -2% | $10,894 | $2.02 | -5,394 | 263,693 | 03 Mar 2026 | Direct |
| Amy Parison | EDIT | Common Stock | Sale | -2.98% | $957 | $2.02 | -474 | 15,434 | 03 Mar 2026 | Direct |
| Linda C. Burkly | EDIT | Common Stock | Sale | -1.09% | $1,513 | $2.02 | -749 | 68,028 | 03 Mar 2026 | Direct |
| Linda C. Burkly | EDIT | Common Stock | Sale | -1.03% | $1,535 | $2.15 | -713 | 68,777 | 03 Dec 2025 | Direct |
| Gilmore Neil O'Neill | EDIT | Common Stock | Sale | -2.04% | $12,064 | $2.15 | -5,603 | 269,087 | 03 Dec 2025 | Direct |
| Amy Parison | EDIT | Common Stock | Sale | -2.82% | $993 | $2.15 | -461 | 15,908 | 03 Dec 2025 | Direct |
| Linda C. Burkly | EDIT | Common Stock | Sale | -1.01% | $1,843 | $2.60 | -710 | 69,490 | 03 Sep 2025 | Direct |
| Amy Parison | EDIT | Common Stock | Sale | -2.72% | $1,189 | $2.60 | -458 | 16,369 | 03 Sep 2025 | Direct |
| Gilmore Neil O'Neill | EDIT | Common Stock | Sale | -2% | $14,517 | $2.60 | -5,592 | 274,690 | 03 Sep 2025 | Direct |
* marks a reported price that did not pass the local price check.